<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Of a series of 100 patients 46 were given combined (i.m. and oral) treatment with ethyl apovincaminate (RGH-4405, Cavinton) in daily doses of 10-30 mg; 54 were put on oral Cavinton (30-45 mg daily) </plain></SENT>
<SENT sid="1" pm="."><plain>Significant and relatively quick improvement was obtained in reversible <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e>, such as hypertensive <z:hpo ids='HP_0001298'>encephalopathy</z:hpo>, intermittent vascular cerebral insufficiency, in the early stage or light cases of cerebral endarteriitis and cerebral <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>On Cavinton effect hypoxic character of the EEG improved, and so did performance in psychodiagnostic tests, alertness and memory in the first place, furthermore changes of the eyeground </plain></SENT>
<SENT sid="3" pm="."><plain>The doses administered did not damage parenchymal organs, they did not cumulate and when used in combination incompatibility could not be observed </plain></SENT>
</text></document>